Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
19.34
+0.68 (3.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
Forte Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 16.1 | 10.62 | 8.3 | 7.63 | 4.22 | 1.38 | |
| Research & Development | 19.53 | 21.86 | 5.59 | 13.85 | 10 | 2.68 | |
| Operating Expenses | 35.63 | 32.49 | 13.9 | 21.49 | 14.23 | 4.06 | |
| Operating Income | -35.63 | -32.49 | -13.9 | -21.49 | -14.23 | -4.06 | |
| Interest & Investment Income | 1.12 | 1.12 | 0.16 | - | - | - | |
| Other Non Operating Income (Expenses) | 0.31 | -0.11 | -0.15 | -0.22 | -0.21 | -0.01 | |
| EBT Excluding Unusual Items | -34.2 | -31.48 | -13.88 | -21.71 | -14.43 | -4.07 | |
| Pretax Income | -34.2 | -31.48 | -13.88 | -21.71 | -46.49 | -4.07 | |
| Net Income | -34.2 | -31.48 | -13.88 | -21.71 | -46.49 | -4.07 | |
| Net Income to Common | -34.2 | -31.48 | -13.88 | -21.71 | -46.49 | -4.07 | |
| Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 0 | 0 | |
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 0 | 0 | |
| Shares Change (YoY) | 82.51% | 81.61% | 24.45% | 89.81% | 249.05% | -76.47% | |
| EPS (Basic) | -18.53 | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | |
| EPS (Diluted) | -18.53 | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | |
| Free Cash Flow | -29.73 | -28.79 | -8.19 | -16.68 | -18.42 | -2.93 | |
| Free Cash Flow Per Share | -16.11 | -22.80 | -11.77 | -29.85 | -62.59 | -34.78 | |
| EBITDA | -35.6 | -32.48 | -13.86 | -21.45 | -14.17 | -4.05 | |
| D&A For EBITDA | 0.04 | 0.01 | 0.04 | 0.04 | 0.05 | 0.01 | |
| EBIT | -35.63 | -32.49 | -13.9 | -21.49 | -14.23 | -4.06 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.